Specialty Biopharmaceuticals & Medical Countermeasures / Contract Manufacturing
Strategic Profile
Chief Executive Officer Joe Papa highlighted substantial progress executing on the company's transformation plan over the past few years, citing operating results, strategic divestitures, margin improvements, and deleveraging through debt repayment. MCM revenue is expected to be flat to slightly down, with management citing continued strength in international demand but noting that 2025 benefited from an "exceptionally strong" $60 million international customer order that is not currently assumed to repeat in 2026.
Cyborg Score Rationale
The company demonstrated strong 2025 operational performance with adjusted EBITDA of $205 million (up 12% year-over-year), gross margin expanded by 900 basis points versus 2024, operating expenses reduced by $140 million, and adjusted net income per share improved to $1.53 from an adjusted loss of $0.23 in 2024. However, 2026 guidance shows revenue projected at $720–$760 million, well below prior expectations, reflecting normalization after exceptional one-time orders.
Top Insights
The company reported 2026 outlook reflects the absence of a major one-time international order that benefited 2025
Net leverage improved to 1.9x from 3.3x at the end of 2024, with $110 million of gross debt paydown during 2025
Recent contracts with the Canadian government valued at approximately $140 million demonstrate continued government demand for medical countermeasures
Board authorized a $50 million stock repurchase program through March 31, 2027